(Q36505754)

English

Patterns of response in patients with pretreated metastatic melanoma who received ipilimumab 3 mg/kg in a European expanded access program: five illustrative case reports

scientific article published on 8 October 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Patterns of response in patients with pretreated metastatic melanoma who received ipilimumab 3 mg/kg in a European expanded access program: five illustrative case reports (English)

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

0 references

expanded access

1 reference

based on heuristic

inferred from title

metastatic melanoma

1 reference

based on heuristic

inferred from title

author name string

Sofie Wilgenhof

1

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Stephanie Du Four

2

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Hendrik Everaert

3

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Bart Neyns

4

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

publication date

8 October 2012

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Cancer Investigation

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

30

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

10

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

712-720

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

New perspectives on the role of vitiligo in immune responses to melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536036

30 September 2017

Cytotoxic T lymphocyte responses against melanocytes and melanoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536036

30 September 2017

Brain metastasis in melanoma: clinical activity of CTLA-4 antibody therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536036

30 September 2017

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536036

30 September 2017

Determinants of survival in patients with brain metastases from cutaneous melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536036

30 September 2017

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536036

30 September 2017

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536036

30 September 2017

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536036

30 September 2017

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536036

30 September 2017

Final version of 2009 AJCC melanoma staging and classification

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536036

30 September 2017

Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536036

30 September 2017

Ipilimumab: controversies in its development, utility and autoimmune adverse events

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536036

30 September 2017

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536036

30 September 2017

Age and gender are significant independent predictors of survival in primary cutaneous melanoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536036

30 September 2017

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536036

30 September 2017

Understanding the response to immunotherapy in humans

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536036

30 September 2017

Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536036

30 September 2017

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536036

30 September 2017

Cerebral metastases of cutaneous melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536036

30 September 2017

Reporting results of cancer treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536036

30 September 2017

A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.727934

21 January 2018

Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy).

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.727934

21 January 2018

Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.727934

21 January 2018

Do we need a different set of response assessment criteria for tumor immunotherapy?

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.727934

21 January 2018

Radiation necrosis of the brain in melanoma patients successfully treated with ipilimumab, three case studies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536036

21 September 2018

A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536036

21 October 2018

Measuring response in solid tumors: unidimensional versus bidimensional measurement

1 reference

https://pubmed.ncbi.nlm.nih.gov/23043499

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3109/07357907.2012.727934

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36505754&oldid=1635732973"